Sep 14, 2021 (Vehement Media via COMTEX) -- The advent of stock screeners in the past decade has made it easier for retail investors to invest in the equity markets. Now, even a newbie investor with little knowledge about stock market investing can access this asset class due to easy-to-use financial analysis tools that were only available to hedge funds and institutions in the recent past.
Finscreener several stock screener tools accelerate an investor's decision-making process. Here, you can look to buy penny stocks , or leverage the ongoing momentum in the equity markets. In this article, we look at three stocks that are trading at a discount of over 100% and are robust bets according to this stock screener .
The first stock on my list is Quotient Limited /zigman2/quotes/202154218/composite QTNT -0.34% , a commercial-stage diagnostics company that develops, manufactures, commercializes, and sells products for the global transfusion diagnostics market in the U.S. and other international markets. It is developing a proprietary technology platform that provides tests for immunohematology, molecular disease screening, and serological disease screening.
QTNT has managed to increase its sales from $24.7 million in fiscal 2018 to $43.37 million in fiscal 2021 that ended in March. While analysts expect sales to decline by 16% year over year to $36.33 million in 2022, it might touch $53.14 million in fiscal 2023.
This growth in sales will also allow Quotient Limited to improve its bottom-line from a loss per share of $1.18 in fiscal 2021 to $0.95 in 2023.
Valued at a market cap of $313 million, the stock is trading at a massive discount to consensus estimates that stand at $10.38 per share. At the time of writing, Quotient Limited stock was trading at a price of $3.08.
A cannabis giant that has grossly underperformed the broader markets in the last two years in HEXO /zigman2/quotes/206508254/composite HEXO -2.81% . However, this pullback also provides investors an opportunity to buy a growth stock at a lower valuation. Canadian cannabis stocks including HEXO have trailed equities since the start of 2019. HEXO stock has in fact lost close to 90% in market value in this period.
Investors should note that the company has managed to increase its sales from $4.93 million in 2018 to $80.78 million in 2020. Bay Street expects sales to touch $128 million in 2021 and $256 million in 2022.
While still unprofitable, HEXO is forecast to narrow its losses from $7.08 per share in 2020 to $0.12 per share in 2021. Similar to most other pot companies in Canada, HEXO has raised equity capital several times in the past, dilute shareholder wealth at a frightening rate which has driven the sell-off.
Investors tracking the stock have a 12-month price target of $6.57 which is higher than its current trading price of $3.08.
Another Canadian stock that makes the list is fintech company Mogo Inc /zigman2/quotes/200234487/composite MOGO +7.20% that's currently valued at a market cap of $478 million. Mogo stock went public back in 2015 and has since returned just over 75% to investors. However, the stock is also down 60% from all-time highs.
Mogo provides digital solutions to consumers who want to improve their financial health. Its Mogo application is a digital spending account that is integrated with the Mogo Visa Platinum Prepaid Card. MogoCrypto allows you to buy and sell Bitcoin while MogoProtect is an ID fraud protection solution. You can also access personal loans via MogoMoney and the company operates a digital payments platform as well.
Analysts covering Mogo stock have a 12-month average target price of $14 for the stock which is over 100% higher than its current trading price of $6.8
Is there a problem with this press release? Contact the source provider Comtex at firstname.lastname@example.org. You can also contact MarketWatch Customer Service via our Customer Center.